<DOC>
	<DOCNO>NCT00416403</DOCNO>
	<brief_summary>RATIONALE : Collecting sample blood tissue patient cancer study laboratory may help doctor learn fluvastatin effect biomarkers related breast cancer . PURPOSE : This randomized phase II trial study fluvastatin effect biomarkers woman undergo surgery ductal carcinoma situ stage I breast cancer .</brief_summary>
	<brief_title>Effect Fluvastatin Biomarkers Women Who Are Undergoing Surgery Ductal Carcinoma In Situ Stage I Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine difference measure cell proliferation ( Ki-67 ) woman ductal carcinoma situ ( DCIS ) stage I breast cancer receive neoadjuvant fluvastatin sodium . Secondary - Determine whether statin use differentially affect specific type DCIS/early-stage breast cancer ( comedo , estrogen receptor [ ER ] -positive , ER-negative ) . - Compare difference tissue stain CD68 , circulate macrophage , regulatory T cell patient . - Assess feasibility use inherent susceptibility ( mRNA polymerase chain reaction test ) predict response statins patient . OUTLINE : This randomize , control , single-blind , multicenter , pilot study . Patients randomize 1 2 treatment arm ( arm I II ) . Patients accrue control participant assign arm III . - Arm I : Patients receive oral fluvastatin sodium daily 3-6 week absence disease progression unacceptable toxicity . - Arm II : Patients receive oral fluvastatin sodium arm I high dose . - Arm III ( control ) : Patients receive fluvastatin sodium . All patient undergo definitive surgery . Patients arm I II undergo blood collection baseline time surgery biomarker analysis . Patients arm III undergo blood collection baseline approximately 1 month later . Tissue collect patient arm time surgery . Blood tissue sample examine biological marker , include Ki-67 , C-reactive protein , cleave caspase 3 , HER2 , CD68 gene , estrogen progesterone receptor immunohistochemistry . Markers inflammation ( e.g. , comedo necrosis macrophage CD25-positive T cell ) , low-density lipoprotein , cholesterol also analyze . Serum mRNA measure polymerase chain reaction . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ductal carcinoma situ ( DCIS ) stage I breast cancer stereotactic core incisional biopsy Planning undergo surgery 36 week Patients undergoing reexcision due evidence tumor present surgical margin eligible Hormone receptor status specify PATIENT CHARACTERISTICS : Female Menopausal status specify ALT AST â‰¤ 10 % upper limit normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able tolerate statin Willing undergo 2 blood draw ( separate approximately 34 week ) study participation ( control arm ) PRIOR CONCURRENT THERAPY : No concurrent statins No concurrent chemotherapy No concurrent administration follow : Niacin Propranolol Cholestyramine Cyclosporine Digoxin Erythromycin Itraconazole Gemfibrozil Phenytoin Diclofenac Tolbutamide Glyburide Losartan Cimetidine Ranitidine Omeprazole Rifampin Warfarin No initiation new hormonal therapy study participation Concurrent participation clinical trial ( e.g. , DCIS prevention ) allow</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>breast cancer situ</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
</DOC>